SEC STATUS

​

Stramsen Biotech, Inc. has been a pioneering force in the biopharmaceutical industry since our inception in November 2020. Over the past three years, we've made significant strides in developing groundbreaking plant-based medicines, positioning ourselves at the forefront of innovation in patient care.

After careful consideration of numerous merger and reverse merger offers from publicly traded companies, we've made a strategic decision to chart our own course towards an Initial Public Offering (IPO). This bold move underscores our confidence in our long-term vision and our commitment to maintaining the stability and integrity of our revolutionary approach to medicine.

We're excited to announce our plans to file an S-1 prospectus with the U.S. Securities and Exchange Commission in early 2025, marking a significant milestone in our journey. As a precursor to this momentous event, we intend to file a Regulation A offering with the SEC in early October 2024, presenting a unique opportunity for investors to be part of our groundbreaking work.

Stramsen Biotech Inc. is poised to raise up to $75,000,000 through our Regulation A offering circular. We're leveraging a strategic combination of private fundraising options, including Regulation D, Regulation A, and Regulation Crowdfunding (CF). This multi-faceted approach allows us to tap into diverse investor pools, maximizing our potential for growth and innovation.

While our primary focus for capital raising will be via private markets, our upcoming IPO serves a crucial purpose: registering our investors' and shareholders' stocks. This approach ensures we can reward those who have believed in our vision from the start while opening doors for new investors to join our journey.

As we prepare for this exciting new chapter, Stramsen Biotech, Inc. is actively seeking partnership with premier investment banks to serve as underwriters for our IPO. We invite interested parties to contact us promptly to explore this exceptional opportunity to be part of a transformative force in biopharmaceuticals.

We're thrilled to announce that we've already taken significant steps towards our public offering. On May 20th, 2024, we filed Form Regulation D Rule 506(c) with the SEC, and we've successfully reserved SRBX as our future trading symbol with NASDAQ. These milestones underscore our commitment to transparency and our readiness for the public market.

For institutional and high-volume investors, we're offering a limited-time opportunity to invest at a special price. With 750 million authorized shares and a recent valuation of $6.5 billion, our current price per share stands at an attractive $8.76. We're open to negotiations and welcome your offers. Our forward-thinking strategy includes plans to reduce our total authorized shares by half, potentially pushing our share price to $17.35  or higher upon going public.

Join us in our mission to revolutionize patient care through plant-based medicines. Invest in Stramsen Biotech, Inc. - where nature meets innovation, and transformation becomes reality.

​

 

​